Kairos Pharma Begins Phase 2 Trial of ENV105 Combo for CRPC

Kairos Pharma, a clinical-stage biopharmaceutical firm, has initiated a Phase 2 clinical trial for its lead drug candidate, ENV105. The trial is testing a combination treatment with apalutamide to combat castrate-resistant prostate cancer (CRPC). The company's CEO, John Yu, highlighted the challenge of drug resistance in cancer treatment and emphasized the design of ENV105 to counteract this issue across various cancer types, including prostate and lung cancer.

The ongoing Phase 2 trial is a randomized, multi-institutional study that aims to compare the effectiveness of the combined therapy of ENV105 and apalutamide against apalutamide alone in treating CRPC. The study plans to include 100 participants who have shown resistance to androgen receptor signaling inhibitors. Traditionally, such patients are treated with chemotherapy combined with androgen signaling inhibition, which can have severe side effects. However, previous studies have indicated that ENV105 could convert 44% of CRPC patients back to castrate sensitivity, prompting the primary goal of this trial to assess the efficacy of the new combination treatment.

Dr. Neil Bhowmick, Kairos Pharma's Chief Scientific Officer, noted that the trial marks the second indication for ENV105 after lung cancer. It is a result of extensive research to understand the drug's mechanism and to build clinical experience with prostate cancer patients.

Kairos Pharma, headquartered in Los Angeles, California, is dedicated to developing a range of innovative oncology therapies designed to overcome the immune-suppressing effects of cancer. The company is progressing its pipeline with drug candidates aimed at reversing resistance and immune suppression caused by cancer.